Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

B7-33 peptide iconB7-3326 residuesVIKLSGRELVRAQIAISGMSTWSKRSLEach bubble = one amino acid. Size = residue mass. Color = chemical class.

B7-33

6 min half-life·Injection·8w on / 4w off

Also known as: single-chain relaxin mimetic, RXFP1 biased agonist

Infarct size cut nearly in half. That's what B7-33 did in mouse hearts after ischemia-reperfusion injury, dropping damage from 45.3% to 22.0% in the Devarakonda 2020 study [1]. B7-33 is a single-chain relaxin-2 analog, a simplified version of the two-chain H2 relaxin hormone that costs a fraction to produce. It targets the RXFP1 receptor with biased agonism, activating pERK1/2 over cAMP. That matters because cAMP drove prostate tumor growth in relaxin studies; B7-33 avoids it. Zero human data exists. All dosing comes from rodent models. The 6-minute serum half-life is a real limitation, and twice-daily injections are likely the minimum for meaningful receptor engagement.

What Is B7-33?

Infarct size dropped from 45.3% to 22.0% (P=0.02) in mice receiving B7-33 after cardiac ischemia-reperfusion. That single data point from Devarakonda and colleagues (n=8-10 per group)[1] captures why this peptide interests fibrosis researchers.

B7-33 (CAS unconfirmed; molecular formula derived from relaxin-2 B-chain residues 7-33) is a synthetic single-chain peptide first described in 2016 by Hossain's group at the Florey Institute and Monash University [2]. Native H2 relaxin requires two chains and three disulfide bonds, an insulin-like architecture that makes production expensive and difficult. B7-33 sidesteps all of that. It's a linear peptide, largely unstructured in solution, that folds into the correct conformation only when it contacts RXFP1.

The mechanism is what separates B7-33 from its parent hormone. It preferentially activates pERK1/2 signaling over cAMP through RXFP1-AT2R heterodimers. This biased agonism drives collagen degradation via MMP-2 upregulation and suppresses TGF-beta1/Smad-mediated fibrosis. In mouse cardiomyopathy models, 7 days of B7-33 reversed left ventricular fibrosis faster than the ACE inhibitor perindopril [3]. It also replicated the vasoprotective effects of serelaxin in rat mesenteric arteries at equimolar doses [4].

The catch: roughly 11-13 papers exist, predominantly from one research group at Monash/Florey. Independent replication is minimal. No human has received B7-33 in any clinical or pharmacokinetic study. The in vitro serum half-life sits at approximately 6 minutes, and a lipidated derivative with 10x stability improvement [5] isn't commercially available. This is a preclinical research compound, full stop.

How B7-33 Works

B7-33 binds RXFP1, a leucine-rich repeat-containing G protein-coupled receptor that normally responds to H2 relaxin. The difference is selectivity. Native relaxin activates both cAMP and pERK1/2 through RXFP1. B7-33 preferentially triggers pERK1/2 with minimal cAMP accumulation in cells that endogenously express the receptor.

The anti-fibrotic pathway runs through RXFP1-AT2R heterodimers. When B7-33 engages these receptor complexes, downstream signaling activates protein phosphatases via pERK1/2. This cascade upregulates MMP-2, a collagen-degrading enzyme that breaks down excess extracellular matrix. At the same time, B7-33 suppresses TGF-beta1/Smad signaling. That blocks myofibroblast differentiation and stops new collagen deposition. The result is a two-pronged attack on fibrosis: clearing existing collagen while preventing new deposits.

In blood vessels, B7-33 stimulates nitric oxide production through endothelial NOS activation. Smooth muscle relaxes. Blood pressure drops. This accounts for the vasoprotective effects confirmed in rat mesenteric artery preparations [4].

During ischemic injury, B7-33 also reduces endoplasmic reticulum stress and limits cardiomyocyte apoptosis. The biased signaling profile (pERK1/2 over cAMP) is the entire therapeutic premise; cAMP-mediated RXFP1 activation expanded prostate size by over 150% in mouse models with native relaxin. B7-33 showed no prostate growth effect [2].

B7-33 Benefits

  • B7-33 benefits center on anti-fibrotic activity and cardioprotection, with all evidence coming from rodent models.
  • Myocardial infarct size reduced from 45.3% to 22.0% with preserved cardiac fractional shortening in mouse ischemia-reperfusion models (Devarakonda et al. 2020, n=8-10 per group)[1].
  • Left ventricular fibrosis reversed faster than perindopril (a standard ACE inhibitor) in mouse isoprenaline-induced cardiomyopathy after just 7 days of treatment (Samuel et al. 2023)[3].
  • Vasoprotective effects matched serelaxin at equimolar doses in rat mesenteric arteries, including NO-dependent vasodilation (Marshall et al. 2017)[4].
  • Fibrotic capsule thickness around implants dropped 49.2% over 6 weeks in a mouse subcutaneous PLGA coating study (Welch et al. 2019)[6].
  • No prostate tumor promotion in vivo, unlike native relaxin-2, due to biased pERK1/2 signaling that avoids cAMP-driven proliferation (Hossain et al. 2016)[2]. This is a notable safety advantage over full RXFP1 agonists.
  • Endothelial dysfunction caused by placental trophoblast conditioned media was prevented in vitro, pointing to potential preeclampsia research applications (Marshall et al. 2017)[4].

B7-33: Science vs Community Consensus

Science Only
Scientific Evidence
Weak
Based on 9 key studies·Research only

Anti-fibrotic and cardioprotective in rodent models via RXFP1 biased agonism (pERK1/2 over cAMP).

Dosing studied: 0.25 mg/kg twice daily SC/IP (mouse reference, PMID 32295457); human allometric extrapolation 100–500 mcg/day
Read the evidence (key study, limitations)

Reduces myocardial infarct size ~50% (45.3% → 22.0%), reverses established LV fibrosis faster than perindopril, replicates serelaxin vasoprotection. Zero human data.

Key Study

Devarakonda et al. 2020 (PMID 32295457): mouse ischemia-reperfusion MI model; B7-33 reduced infarct size from 45.3% to 22.0% (P=0.02) and preserved fractional shortening at 7 days

Limitations

~11-13 papers total, predominantly from one Monash/Florey Institute group with minimal independent replication; zero human PK or safety data; 6-min in vitro serum t½ limits SC exposure window; no in vivo PK published; lipidated formulation (10× stability improvement) not commercially available

Community Experience
Weak
3.5/5
Based on none: no documented human use cases as of April 2026

No self-experimentation community exists for B7-33.

Community dosing: No established community protocol
Read the reports (what users report 2, common issues 5)

Zero Reddit threads found (search: r/Peptides, r/nootropics, general Reddit). Discussed only in academic literature and occasionally in bodybuilding forums as a theoretical anti-fibrotic without reported personal use.

What users report (2)
  • Theoretical anti-fibrotic potential extrapolated from mouse cardiac models (no community confirmation)
  • Biased agonism profile (no prostate tumor promotion) cited as theoretical safety advantage over native relaxin
Common issues (5)
  • 6-minute serum half-life makes sustained SC exposure uncertain: once-daily injection almost certainly inadequate based on mouse studies
  • No human PK data: SC bioavailability completely unknown
  • Extremely limited availability; high per-mg cost relative to evidence certainty
  • No independent replication outside original Monash/Florey group
  • Lipidated derivative (10× stability) not commercially available: only standard B7-33 is sold for research
Science-Only Evidence

B7-33 has no community self-experimentation base. All data originates from academic preclinical research. The 6-min serum half-life and extreme niche status have prevented any measurable community adoption.

B7-33 Dosage Guide

SpeculativeZero human data: dose based on preclinical research
LevelDose / InjectionFrequency
Beginner100 mcg
DailyTrack
Moderate250 mcg
DailyTrack
Aggressive500 mcg
DailyTrack
Note:

Your first vial of B7-33 will likely be 2 mg. Add 2 mL of bacteriostatic water and you get 1 mg/mL (1000 mcg/mL). On a standard insulin syringe, 10 units equals 100 mcg (beginner dose) and 25 units equals 250 mcg (moderate dose). If you find a 5 mg vial, adding 2 mL gives you 2.5 mg/mL; then 100 mcg is 4 units and 250 mcg is 10 units.

The thing most people miss with B7-33 is the dosing frequency. The 6-minute serum half-life means once-daily injection is almost certainly not enough. The published mouse protocol used 0.25 mg/kg twice daily, 12 hours apart. If you're only injecting once a day, you're probably not getting meaningful RXFP1 engagement throughout the day.

Reconstituted B7-33 degrades fast at room temperature. Keep it at 2-8 degrees C and use it within 7-10 days. Prepare only the dose you need per session. The short half-life reflects real susceptibility to proteolysis; this isn't a peptide that tolerates sloppy storage.

The quality benchmark is an HPLC/MS Certificate of Analysis showing 98% purity minimum. Degraded B7-33 looks identical to active peptide without mass spectrometry analysis.

Cycling Protocol

On Period
8 weeks
Off Period
4 weeks

No established cycling protocol exists for B7-33 in any species. Animal studies used continuous daily dosing for 7-14 day treatment windows (e.g., days 7-14 post-injury in cardiomyopathy models). The 8-on/4-off suggestion is a conservative placeholder based on general peptide cycling conventions. Researchers should follow study-specific dosing timelines.

Calculate your B7-33 dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

B7-33 Protocols by Goal

advancedCommunity4-8 weeks (based on mouse cardiomyopathy and implant study timelines; human remodeling timelines unknown and likely substantially longer)
Mouse reference protocol
Wk 1-2
0.25 mg/kg per injection · Twice daily, 12h apart · Subcutaneous (SC) or intraperitoneal (IP)
Human extrapolation: conservative (research use)
Wk 4-8
100–250 mcg per injection · Twice daily, 12h apart · Subcutaneous

Expected: Unknown in humans. Mouse studies show measurable anti-fibrotic effect at 7-14 days. Human fibrosis resolution (via MMP-2 upregulation / TGF-β suppression) expected to require weeks to months.

Monitor: Monitor blood pressure: vasodilatory effects (NO-mediated eNOS activation) are expected. No other validated monitoring parameters exist for human use.

How to Use B7-33

  1. 1
    Step 1

    Gather your supplies: B7-33 vial (lyophilized), bacteriostatic water, alcohol swabs, insulin syringe (29-31 gauge).

  2. 2
    Reconstitute the peptide

    For a 2 mg vial, add 2 mL of bacteriostatic water slowly down the side of the vial. Do not shake. Swirl gently until dissolved. This gives you 1 mg/mL (1000 mcg/mL).

  3. 3
    Calculate your dose

    At 1 mg/mL concentration: 100 mcg equals 10 units on an insulin syringe. 250 mcg equals 25 units. 500 mcg equals 50 units (half the syringe on a 100-unit insulin syringe).

  4. 4
    Draw your dose with an insulin syringe

    Pull the plunger to the correct unit marking.

  5. 5
    Inject subcutaneously in the abdominal area

    Pinch a fold of skin, insert the needle at a 45-degree angle, inject slowly. Rotate injection sites with each dose.

  6. 6
    Step 6

    The published mouse protocol calls for dosing every 12 hours (twice daily). Morning and evening injections, roughly 12 hours apart, best approximate the validated animal schedule.

  7. 7
    Step 7

    Store reconstituted vial at 2-8 degrees C immediately after use. Do not leave at room temperature. Use within 7-10 days. Discard if the solution becomes cloudy or shows particles.

  8. 8
    Step 8

    Monitor blood pressure at baseline, after the first dose, and weekly. Sit or lie down for 10-15 minutes post-injection if you experience lightheadedness.

Alternative Routes

Nanoparticle oral (SPION-conjugated: research only)

Oral dosing every 72h over 4 weeks showed anti-fibrotic efficacy ≥ perindopril in murine cardiomyopathy model (PMID 41382190). Standard unconjugated B7-33 has no oral bioavailability.

Requires conjugation to glycinated superparamagnetic iron oxide nanoparticles (SPION). Mechanism: phagocytosis by RXFP1-expressing dendritic cells enables sustained intracellular delivery. Not purchasable: research synthesis only. Do not attempt oral dosing with standard research-grade B7-33.

Lipidated derivative SC (AcK(PalmGlu)-PEG12-B7-33: research only)

In vitro half-life extended from 6 to 60 minutes via albumin binding (10× improvement, PMID 37047588). In vivo PK data not yet published.

Exists only in published Monash group synthesis protocols. This formulation is not sold anywhere. Standard research-grade B7-33 is the only commercially available form.

Mixing your own vial? Use the B7-33 reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

B7-33 Stacking Protocols

Works With

Avoid

ACE inhibitors / ARBs (e.g., lisinopril, ramipril, losartan, valsartan)

B7-33 activates RXFP1-AT2R heterodimers, modulating the renin-angiotensin system. Additive hypotension risk and potentially altered AT2R signaling dynamics.

Nitrate medications (nitroglycerin, isosorbide dinitrate)

B7-33 upregulates endothelial NO via eNOS activation. Combined with nitrate donors, risk of excessive vasodilation and hypotensive crisis.

Do not combine
Calcium channel blockers (amlodipine, nifedipine, etc.)

Overlapping vasodilatory mechanisms. Additive blood pressure reduction; hypotension risk particularly at higher B7-33 doses.

Estimated Cost

B7-33 Side Effects

No human has ever received B7-33 in a clinical setting. Every safety inference below comes from animal pharmacology or from the known profile of serelaxin (recombinant H2 relaxin), which targets the same receptor but with different signaling bias. Treat all of this as theoretical risk assessment, not documented adverse events.

The primary pharmacological risk is hypotension. B7-33 activates endothelial NOS, producing nitric oxide and vasodilation. If you're on ACE inhibitors, ARBs, calcium channel blockers, or nitrate medications, additive blood pressure drops are a real concern. Serelaxin in human heart failure trials (RELAX-AHF) caused mild nausea, headache, and hypotension. B7-33's signaling profile differs, but RXFP1-mediated vasodilation is shared.

The 6-minute in vitro serum half-life is actually a double-edged consideration for safety. Systemic exposure after each subcutaneous injection is brief, which may limit adverse effects. But it also means any sustained effect requires twice-daily dosing, doubling injection site exposure.

Injection site reactions are expected with repeated subcutaneous administration of any research peptide. B7-33's immunogenicity is completely uncharacterized. Persistent nodules, erythema, or induration at injection sites warrant stopping.

Long-term toxicology studies have not been published for B7-33 in any species. The total preclinical literature is roughly 11-13 papers, predominantly from one research group. MMP-2 upregulation (the anti-fibrotic mechanism) could theoretically affect vascular integrity if sustained at high levels; the interaction with anticoagulants is uncharacterized.

Reproductive safety is unknown. Relaxin signaling plays a role in gestational physiology, and exogenous RXFP1 activation during pregnancy could disrupt normal processes. B7-33 is contraindicated in pregnancy and breastfeeding.

For anyone with active malignancy: although B7-33 avoided prostate tumor promotion unlike native relaxin, the safety profile in cancer contexts is not established. The 6 papers showing no tumor growth were conducted in specific prostate models, not across cancer types.

When to stop: symptomatic hypotension (dizziness, presyncope, lightheadedness), progressive injection site reactions, or any unexpected systemic symptoms. Given zero human safety data, the threshold for stopping should be low.

Common Issues & Solutions

No perceived effect: Once-daily injection almost certainly provides insufficient RXFP1 exposure given the 6-min serum t½. Switch to twice-daily (12h apart) to match the published mouse protocol: this is the primary likely cause of lack of effect.

Hypotension / dizziness / lightheadedness: Expected on-target pharmacological effect from NO-mediated vasodilation. Reduce dose, ensure adequate hydration, avoid combining with antihypertensive medications. Sit or lie down at injection time if orthostatic symptoms occur.

Rapid peptide degradation: Reconstituted B7-33 is susceptible to protease degradation. Keep refrigerated at 2-8°C; use within 7-10 days; never leave at room temperature; prepare only the dose needed per session. The 6-min in vitro serum t½ reflects real susceptibility to proteolysis.

Unknown systemic exposure: No SC bioavailability data has been published for B7-33 in any species. Systemic exposure after SC injection is theoretically limited by rapid serum proteolysis: this is an inherent research limitation, not a product quality issue. A lipidated derivative (10× stability) exists in literature but is not purchasable.

High per-dose cost: At twice-daily dosing (500 mcg/day total), a 6 mg vial lasts ~12 days. Minimize waste by reconstituting only what is needed and storing reconstituted solution optimally.

Ask AI about this page

Ask AI for a second opinion on B7-33 dosing and side effects

Contraindications

  • Pregnancy and breastfeeding: relaxin signaling plays a role in reproductive physiology; exogenous RXFP1 activation may disrupt normal gestational processes
  • Hypotension or concurrent use of antihypertensive medications: B7-33 promotes NO-dependent vasodilation and may cause additive blood pressure reduction
  • Active malignancy, particularly hormone-sensitive cancers: although B7-33 did not promote prostate tumor growth unlike native relaxin, the safety profile in cancer contexts is not established
  • Severe hepatic or renal impairment: peptide metabolism and clearance pathways are not characterized in compromised organ function
  • Known hypersensitivity to relaxin-derived peptides or any component of the formulation

Drug Interactions

  • ACE inhibitors and ARBs: B7-33 activates RXFP1-AT2R heterodimers and modulates the renin-angiotensin system; additive hypotensive effects and altered AT2R signaling are possible
  • Nitrate medications (nitroglycerin, isosorbide): B7-33 promotes NO production via eNOS activation; combined use may cause excessive vasodilation and hypotension
  • Anticoagulants and antiplatelet agents: MMP-2 upregulation by B7-33 could theoretically affect vascular integrity and bleeding risk, though this interaction is uncharacterized
  • Calcium channel blockers: additive blood pressure lowering due to overlapping vasodilatory mechanisms
  • Immunosuppressants: unknown interactions; B7-33 modulates inflammatory and fibrotic pathways that may intersect with immunosuppressive drug targets

Product Quality

Recommended Monitoring

TestWhenTarget
Blood pressure (manual cuff or ambulatory monitor)Baseline, then after first dose, then weekly during the dosing periodSystolic >90 mmHg seated; stop use immediately if symptomatic hypotension occurs
Injection site assessmentEach injection; weekly visual inspectionNot listed
Blood pressure (manual cuff or ambulatory monitor)

B7-33 promotes NO-dependent vasodilation via eNOS activation and RXFP1-AT2R signaling. Hypotension is the primary expected pharmacological risk in any human use context.

Injection site assessment

Repeated SC injections of an immunologically uncharacterized peptide carry unknown local reaction risk. Persistent nodules, erythema, or induration may indicate local immune response.

B7-33 Before and After

Days 1-3

No observable effects expected at this stage; peptide exposure establishing in tissue. Based on animal model timelines.

Days 3-7

In mouse MI models, measurable cardioprotection (reduced infarct size, preserved fractional shortening) was evident by day 7 post-treatment.

Weeks 1-2

In cardiomyopathy models, 7 days of B7-33 treatment (days 7-14) reduced left ventricular fibrosis and inflammation, matching the efficacy of native relaxin.

Weeks 2-4

Continued anti-fibrotic remodeling expected with sustained dosing; collagen degradation via MMP-2 upregulation is a gradual process.

Weeks 4-6

In implant studies, 6 weeks of B7-33 release produced a 49% reduction in fibrotic capsule thickness. Maximum anti-fibrotic benefit likely requires sustained multi-week exposure.

What to Expect

Days 1-3, Establishing RXFP1 exposure: Don't expect to feel or see anything anti-fibrotic at this stage. Receptor occupancy starts with each dose, but tissue-level collagen remodeling hasn't begun. The one thing that is pharmacologically immediate is vasodilation from NO production. Some blood pressure reduction and warmth are plausible within hours of injection, especially at higher doses or if you're on antihypertensives.

Days 3-7, Early cardioprotective window: In the mouse MI model [1], measurable cardioprotection was already evident by day 7 of treatment. Infarct size was reduced, fractional shortening preserved. Human timing is completely unknown and likely substantially longer. Injection site reactions may start appearing with repeated dosing.

Weeks 1-2, Anti-fibrotic activity phase: The mouse cardiomyopathy study [3] treated animals from days 7-14 post-injury. Seven days of B7-33 significantly reduced left ventricular fibrosis and outperformed perindopril. Translating rodent fibrotic remodeling to human timelines is speculative; human fibrosis resolution occurs over weeks to months, not days. Immunogenicity risk (uncharacterized) increases with continued administration.

Weeks 4-8, Sustained remodeling phase: The implant coating study [6] needed 6 weeks of continuous B7-33 release to achieve that 49.2% reduction in fibrotic capsule thickness. The oral nanoparticle study [7] dosed every 72 hours for 4 weeks and matched perindopril's anti-fibrotic efficacy. MMP-2-mediated collagen degradation is a gradual biological process. If B7-33 works in humans at all, the full effect likely requires sustained multi-week exposure that the 6-minute half-life makes challenging to achieve with standard subcutaneous injection.

Detailed Timeline: Science vs Community

Days 1-3
Science

Receptor occupancy begins with each dose. No measurable tissue-level anti-fibrotic effects expected at this stage based on mouse model timelines. Vasodilation (NO-dependent) is pharmacologically immediate.

Community

No community data. Vasodilatory effects (warmth, mild blood pressure reduction) are theoretically plausible within hours of dosing.

Days 3-7
Science

In mouse MI (ischemia-reperfusion) models, measurable cardioprotection, reduced infarct size and preserved fractional shortening, was evident by day 7 post-treatment start (PMID 32295457). Timing in humans completely unknown.

Community

No community data.

Weeks 1-2
Science

7 days of B7-33 in mouse isoprenaline-induced cardiomyopathy (treatment days 7-14 post-injury) significantly reduced LV fibrosis and inflammation, outperforming the ACE inhibitor perindopril (PMID 36753958). Human fibrotic remodeling occurs over weeks to months.

Community

No community data.

Weeks 4-8
Science

PLGA implant coating studies showed 49.2% reduction in fibrotic capsule thickness at 6 weeks with continuous B7-33 release (PMID 31713411). MMP-2-mediated collagen degradation and TGF-β/Smad suppression are gradual biological processes. Nanoparticle oral dosing every 72h showed anti-fibrotic efficacy ≥ perindopril over 4 weeks in mice (PMID 41382190).

Community

No community data. Human fibrosis resolution timelines are substantially longer than rodent models.

Pharmacokinetics

Half-Life
6min
Bioavailability
Unknown: no subcutaneous bioavailability studies published. The short serum half-life suggests rapid degradation by serum proteases.
Tmax
Unknown: no pharmacokinetic absorption studies published for B7-33 via any route
Data Confidence
low

Source: In vitro serum half-life of ~6 minutes, reported by Praveen et al. 2023 (PMID 37047588). No in vivo PK data published.

Pharmacokinetics: Active Dose Over Time

t½ = ~6 minutes in vitro (native peptide; rapid serum degradation)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
26
Sequence
VIKLSGRELVRAQIAISGMSTWSKRSL
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: Unconfirmed (PubChem CID 162662592 lists 1818415-56-3 as a synonym)

Who Should Consider B7-33

  • Cardiovascular disease researchers studying myocardial fibrosis and post-infarction remodeling
  • Investigators studying organ fibrosis (cardiac, pulmonary, renal) and TGF-beta/Smad pathway modulation
  • Vascular biology researchers examining endothelial function and NO-mediated vasodilation
  • Biomaterials scientists developing anti-fibrotic implant coatings
  • Reproductive biology researchers studying preeclampsia and vascular dysfunction in pregnancy models

Related Peptides

What Changed for B7-33

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations

References

  1. [1]B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1 (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation (opens in a new tab)PubMed (opens in a new tab)PubMed
  7. [7]Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration (J Biomed Sci 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Stable at -20°C for long-term storage (12+ months); protect from light and moisture
After Reconstitution
Use within 7-10 days; store at 2-8°C. The short serum half-life indicates susceptibility to degradation: avoid repeated freeze-thaw cycles
Temperature
-20°C (lyophilized); 2-8°C (reconstituted)

Frequently Asked Questions

Based on the published mouse protocol (0.25 mg/kg twice daily, 12 hours apart), twice-daily dosing is the experimentally validated schedule. The extremely short in vitro half-life means a single-injection model likely fails to maintain enough receptor engagement. In vivo half-life may be somewhat longer, but no in vivo PK data has been published.

B7-33 and H2 relaxin are mechanistically distinct despite targeting the same receptor. H2 relaxin activates both cAMP and pERK1/2 pathways; B7-33 is a biased agonist that preferentially activates pERK1/2 with minimal cAMP. This matters because cAMP activation increased prostate size by over 150% in mouse models with H2 relaxin, while B7-33 showed no prostate growth effect.

The preclinical literature shows reversal of established fibrosis in cardiac and lung models, in addition to prevention. But tissue remodeling timelines, required sustained exposure, and efficacy in human fibrotic disease are completely unknown. Rodent timelines likely underestimate human requirements.

The lipidated derivative extends in vitro half-life from 6 to 60 minutes via albumin binding. However, it is not commercially available; it exists only in published synthesis protocols from the Monash group and remains a lab-only compound as of 2025.

No. The 2025 paper (PMID 41382190) demonstrated oral efficacy using B7-33 conjugated to glycinated SPION nanoparticles. Free B7-33 taken orally would be destroyed by gastric acid and GI proteases before absorption; the nanoparticle encapsulation is what enables oral delivery.